We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Multinational pharmaceutical companies present in India are spearheading
the shift away from the country's traditional drug manufacturing centres, and
are increasingly obliging their contract manufacturers to relocate.
Par Pharmaceutical Companies today announced that it has entered into a purchase
agreement to acquire a 16 percent partnership interest in Optimer Pharmaceuticals.
Memory Pharmaceuticals today announced that it has received a $2.0 million milestone
payment from Roche related to the companies' Nicotinic Alpha-7 Collaboration,
a 2003 strategic alliance focused on the development of nicotinic alpha-7 receptor
agonists for the treatment of neurological and psychiatric disorders.
Biovail is cutting about 440 jobs, or 20 per cent of its workforce, after selling
U.S. commercial operations and product lines to Kos Pharmaceuticals of Cranbury,
N.J.
Indian pharma exports are projected to grow to $6 billion by 2015 from its current
level of less than US$2bn, provided the domestic drugs industry maintain a consistency
in its present export growth of 20% per annum, an ASSOCHAM release said on Tuesday.
Alcan announced today the expansion
of its packaging network in Spain through a new production centre dedicated
to pharmaceutical packaging at its Alcan Packaging Alzira plant, located near
Valencia, The center will specialise in printing flexible packaging materials.
Israeli intellectual property specialists have claimed that the country's
new patent law is set to have a counter-productive effect, and could lead to
"aggressive" US retaliation on patent violations.
Brazil's system of drug-price controls has come under attack from
all sides of the debate, with members of both the left-wing ruling party and
industry associations adding to the criticism.
Amid the ongoing controversy over parallel drug imports in the US,
and the prospect of the forthcoming Prescription Market Access and Drug Safety
Act, a UK-based industry expert has outlined current threats posed by parallel
imports.